Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 199, Issue 7, 2019, Pages 863-872

  Bhatraju, Pavan K ^a,b   Zelnick, Leila R ^b   Herting, Jerald ^c   Katz, Ronit ^b   Mikacenic, Carmen ^a   Kosamo, Susanna ^a   Morrell, Eric D ^a   Robinson Cohen, Cassianne ^b   Calfee, Carolyn S ^d,e   Christie, Jason D ^f   Liu, Kathleen D ^e   Matthay, Michael A ^d,e   Hahn, William O ^g   Dmyterko, Victoria ^a   Slivinski, Natalie S J ^h   Russell, Jim A ⁱ   Walley, Keith R ⁱ   Christiani, David C ^j,k   Liles, W Conrad ^c   Himmelfarb, Jonathan ^b   Wurfel, Mark M ^a,b   more..

^a Divisions of Pulmonary and Critical Care Medicine   (United States)

^b Division of Nephrology   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Allergy and Infectious Diseases   (United States)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Acute kidney injury; Endothelial dysfunction; Mortality; Subphenotypes

Indexed keywords

ANGIOPOIETIN 1; CREATININE; INTERLEUKIN 8; NORADRENALIN; VASOPRESSIN; BIOLOGICAL MARKER; VASOPRESSIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; APACHE; ARTICLE; CANCER PROGNOSIS; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KIDNEY FUNCTION; LATENT CLASS ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; URINE VOLUME; AGED; BLOOD; GENETICS; PATHOPHYSIOLOGY; WASHINGTON;

ACUTE KIDNEY INJURY; AGED; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; VASOPRESSINS; WASHINGTON;

EID: 85063660912     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201807-1346OC     Document Type: Article

References (45)

1. Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore PM, Hoste E, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 2017;43:730-749.
2. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370.
3. Nisula S, Kaukonen K-M, Vaara ST, Korhonen A-M, Poukkanen M, Karlsson S, et al.; FINNAKI Study Group. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med 2013;39: 420-428.
4. Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, et al.; Kidney Disease: Improving Global Outcomes. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney Int 2015;88:447-459.
5. Barasch J, Zager R, Bonventre JV. Acute kidney injury: a problem of definition. Lancet 2017;389:779-781.
6. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-620.
7. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al.; ARDS Network. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195: 331-338.
8. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al.; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-323.
9. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098.
10. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358: 877-887.
11. Bhatraju PK, Robinson-Cohen C, Himmelfarb J, Wurfel MM. Latent class analysis identifies AKI sub-phenotypes with differing biomarker profiles of endothelial dysfunction and relation to risk of death and need for renal replacement therapy [abstract]. J Am Soc Nephrol Abstr Suppl 27:244A.
12. Glavan BJ, Holden TD, Goss CH, Black RA, Neff MJ, Nathens AB, et al.; ARDSnet Investigators. Genetic variation in the FAS gene and associations with acute lung injury. Am J Respir Crit Care Med 2011; 183:356-363.
13. Russell JA, Lee T, Singer J, Boyd JH, Walley KR; Vasopressin and Septic Shock Trial (VASST) Group. The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. Crit Care Med 2017;45:940-948.
14. Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 2013;17:204.
15. Thomas ME, Blaine C, Dawnay A, Devonald MAJ, Ftouh S, Laing C, et al. The definition of acute kidney injury and its use in practice. Kidney Int 2015;87:62-73.
16. Bouchard J, Macedo E, Soroko S, Chertow GM, Himmelfarb J, Ikizler TA, et al.; Program to Improve Care in Acute Renal Disease. Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2010;25:102-107.
17. Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettilä V, Prowle JR, et al. Renal recovery after acute kidney injury. Intensive Care Med 2017;43:855-866.
18. Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009;20:239-244.
19. Liu KD, Glidden DV, Eisner MD, Parsons PE, Ware LB, Wheeler A, et al.; National Heart, Lung, and Blood Institute ARDS Network Clinical Trials Group. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007;35:2755-2761.
20. Robinson-Cohen C, Katz R, Price BL, Harju-Baker S, Mikacenic C, Himmelfarb J, et al. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care 2016;20:207.
21. Bagshaw SM, George C, Gibney RTN, Bellomo R. A multi-center evaluation of early acute kidney injury in critically ill trauma patients. Ren Fail 2008;30:581-589.
22. Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015;41: 1411-1423.
23. Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling 2007;14: 535-569.
24. Nguyen HQ, Herting JR, Pike KC, Gharib SA, Matute-Bello G, Borson S, et al. Symptom profiles and inflammatory markers in moderate to severe COPD. BMC Pulm Med 2016;16:173.
25. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Series B Stat Methodol 2011;73:273-282.
26. Xu K, Rosenstiel P, Paragas N, Hinze C, Gao X, Shen TH, et al. Unique transcriptional programs identify subtypes of AKI. J Am Soc Nephrol 2017;28:1729-1740.
27. Kellum JA, Sileanu FE, Bihorac A, Hoste EA, Chawla LS. Recovery after acute kidney injury. Am J Respir Crit Care Med 2017;195:784-791.
28. Bhatraju PK, Mukherjee P, Robinson-Cohen C, O'Keefe GE, Frank AJ, Christie JD, et al. Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death. Crit Care 2016;20:372.
29. Bellomo R, Bagshaw S, Langenberg C, Ronco C. Pre-renal azotemia: a flawed paradigm in critically ill septic patients? Contrib Nephrol 2007;156:1-9.
30. Uchino S. The meaning of transient azotemia. Contrib Nephrol 2010; 165:337-344.
31. Jongman RM, van Klarenbosch J, Molema G, Zijlstra JG, de Vries AJ, van Meurs M. Angiopoietin/Tie2 dysbalance is associated with acute kidney injury after cardiac surgery assisted by cardiopulmonary bypass. PLoS One 2015;10:e0136205.
32. Kümpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med 2010;36:462-470.
33. Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest 2013;123:3436-3445.
34. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011;39:702-710.
35. Parikh SM, Mammoto T, Schultz A, Yuan H-T, Christiani D, Karumanchi SA, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006;3:e46.
36. David S, Park J-K, Meurs Mv, Zijlstra JG, Koenecke C, Schrimpf C, et al. Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 2011;55:251-259.
37. Kim DH, Jung YJ, Lee AS, Lee S, Kang KP, Lee TH, et al. COMPangiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney Int 2009;76:1180-1191.
38. Han S, Lee S-J, Kim KE, Lee HS, Oh N, Park I, et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med 2016;8:335ra55.
39. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12: 235-239.
40. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256: F274-F278.
41. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582.
42. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al.; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016;316: 509-518.
43. Chen S, Li H, Zhang C, Li Z, Wang Q, Guo J, et al. Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus. Int J Endocrinol 2015;2015:163120.
44. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant 2010;25:3948-3956.
45. Tarakçioǧlu M, Erbaǧci AB, Usalan C, Deveci R, Kocabaş R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm 2003;12:15-19.